secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001737287-23-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports Q4 2022 net loss $94.8M, cash $576.5M; pipeline advances
-------------------------------------------------------------------------

- Net loss Q4 2022 $94.8M ($0.66/share); full year net loss $332.6M ($2.32/share).
- Cash, cash equivalents and investments $576.5M as of Dec 31, 2022; expects 2023 cash burn ~$250M, runway into 2025.
- Initiated ALPHA2 Phase 2 trial of ALLO-501A in R/R LBCL; enrollment expected to complete 1H 2024.
- Phase 1 data: ALLO-501A single dose FCA90 showed 67% ORR, 58% CR rate, median DoR 23.1 months.
- UNIVERSAL trial of ALLO-715 in R/R MM: 67% ORR, 42% VGPR+ rate, median DoR 9.2 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000017/0001737287-23-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000017/allo-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer